What is Clyde Biosciences?
Clyde Biosciences operates at the intersection of biotechnology and regulatory compliance, specializing in advanced cardiomyocyte assays. Central to its value proposition is the CellOPTIQ platform, a sophisticated tool designed to generate human-relevant functional data that informs drug safety and efficacy profiles. By mitigating the risks associated with cardiovascular liabilities, the company provides an essential service that accelerates the path from discovery to clinical application.
As the only validated contract research organization for the CiPA Assay, Clyde Biosciences occupies a unique niche in the market. Their comprehensive suite of services, ranging from primary screening to mechanistic toxicity assays, supports both major pharmaceutical corporations and regulatory bodies. This dual-focus approach ensures that their methodologies are not only scientifically rigorous but also aligned with the evolving standards of global health authorities.
How much funding has Clyde Biosciences raised?
Clyde Biosciences has raised a total of $2.9M across 1 funding round:
Series A
$2.9M
Series A (2015): $2.9M with participation from Epidarex Capital
Key Investors in Clyde Biosciences
Epidarex Capital
Epidarex is a transatlantic venture capital firm focused on building breakthrough life science companies in emerging hubs. The firm is led by a diverse team of early-stage investors who act as trusted partners to founders and co-investors.
What's next for Clyde Biosciences?
With the recent influx of capital, Clyde Biosciences is well-positioned to enhance its technological infrastructure and broaden its service offerings. The strategic focus will likely center on scaling the CellOPTIQ platform to meet the increasing demand for high-throughput, predictive cardiac safety screening. By leveraging its status as a validated CiPA partner, the company is poised to influence future regulatory frameworks, potentially setting new benchmarks for safety in drug development.
Looking ahead, the firm's ability to reduce costs and risks for its partners will remain a primary driver of its long-term growth. As the biopharmaceutical sector continues to prioritize precision medicine and early-stage toxicity assessment, Clyde Biosciences is expected to play an increasingly pivotal role in the global drug discovery ecosystem, bridging the gap between laboratory innovation and patient safety.
